I-123 metaiodobenzylguanidine(I-123 metaiodobenzylguanidine) - 在研适应症：慢性心力衰竭_专利_临床

概要

基本信息

药物类型

诊断用放射药物

别名-

靶点-

作用方式-

作用机制-

治疗领域

心血管疾病

在研适应症

慢性心力衰竭

非在研适应症-

原研机构

Osaka Medical College

在研机构

Osaka Medical College

非在研机构-

最高研发阶段临床阶段不明

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 I-123 metaiodobenzylguanidine 相关的临床试验

NCT01250912

/ CompletedN/AIIT

Three Dimension Neuron Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Ventricular Tachycardia Ablations

Some patients are at risk for life-threatening fast heart rates. These can frequently be treated by using a catheter inside the heart to burn away the cells that create the fast heart rates. The purpose of this study is to image the nerves inside the heart of those patients. The investigators want to find out if abnormalities in the nervous system in the heart can help the physician to find the area that needs to be burnt away.

开始日期2010-03-01

申办/合作机构

University of Maryland Baltimore

[+1]

100 项与 I-123 metaiodobenzylguanidine 相关的临床结果

登录后查看更多信息

100 项与 I-123 metaiodobenzylguanidine 相关的转化医学

登录后查看更多信息

100 项与 I-123 metaiodobenzylguanidine 相关的专利（医药）

登录后查看更多信息

14

项与 I-123 metaiodobenzylguanidine 相关的文献（医药）

2021-04-01·Journal of Nuclear Cardiology3区 · 医学

Cardio-pulmonary involvement in pulmonary arterial hypertension: A perfusion and innervation scintigraphic evaluation

3区 · 医学

Article

作者: Bauleo, Carolina ; Monti, Simonetta ; Bertasi, Michelangelo ; Gimelli, Alessia ; Marzullo, Paolo ; Formichi, Bruno ; Prediletto, Renato ; Airò, Edoardo ; Pugliese, Nicola Riccardo

BACKGROUNDPulmonary arterial hypertension (PAH) is characterized by the right ventricle (RV) remodeling and pulmonary endothelial dysfunction. We studied cardiac perfusion and innervation in PAH with a cadmium-zinc-telluride (CZT) scanner and lung uptake impairment of ¹²³I-metaiodobenzylguanidine (¹²³I-MIBG).METHODSIn 13 patients with newly diagnosed PAH and 11 dilated cardiomyopathies (DCM, for comparative purposes), we assessed early and delayed ¹²³I-MIBG uptake ratios of lung-to-mediastinum (L/M) and heart-to-mediastinum (H/M) on anterior planar images. A quantitative myocardial innervation with ¹²³I-MIBG and perfusion with ^99mTc-tetrofosmin using CZT-SPECT was performed. All patients underwent right heart catheterization.RESULTSEarly and delayed L/M ratios in PAH were lower than DCM (1.47 ± 0.14 vs 1.98 ± 0.11 and 1.40 ± 0.13 vs 1.83 ± 0.09; P < .001), while early and delayed H/M were impaired but not different (1.73 ± 0.20 vs 1.65 ± 0.18 and 1.73 ± 0.27 vs 1.58 ± 0.19). RV perfusion and early innervation were significantly higher in PAH compared to DCM (68.4 ± 13.4 vs 28.6 ± 4.1 and 58.8 ± 9.3 vs 27 ± 2.2; P < .001); delayed RV innervation was not evaluable. RV/LV perfusion and innervation ratios were significantly related (R = 0.74; P < .0001) and had a significant correlation with clinical, hemodynamic, and morpho-functional parameters, including L/M ratios.CONCLUSIONCardio-pulmonary scintigraphy through a perfusion and innervation study is feasible and may identify pulmonary vascular and RV remodeling, as in PAH.

2020-10-01·Journal of Nuclear Cardiology

Cardiac innervation imaging as a risk stratification tool for potential device therapy candidates

Communications

作者: Werner, Rudolf A

As a scintigraphic approach evaluating cardiac nerve integrity, ¹²³I-metaiodobenzylguanidine (¹²³I-mIBG) has been recently Food and Drug Administration approved. A great deal of progress has been made by the prospective ADMIRE-HF trial, which primarily demonstrated the association of denervated myocardium assessed by ¹²³I-mIBG and cardiac events. However, apart from risk stratification, myocardial nerve function evaluated by molecular imaging should also be expanded to other clinical contexts, in particular to guide the referring cardiologist in selecting appropriate candidates for specific therapeutic interventions. In the present issue of the Journal of Nuclear Cardiology^®, the use of ¹²³I-mIBG for identifying cardiomyopathy patients, which would most likely not benefit from ICD due to low risk of arrhythmias, is described. If we aim to deliver on the promise of cardiac innervation imaging as a powerful tool for risk stratification in a manner similar to nuclear oncology, studies such as the one reviewed here may imply an important step to lay the proper groundwork for a more widespread adoption in clinical practice.

2018-11-01·The British Journal of Radiology3区 · 医学

Theranostic radiopharmaceuticals: established agents in current use

3区 · 医学

Review

作者: Ballinger, James R

Although use of the term "theranostic" is relatively recent, the concept goes back to the earliest days of nuclear medicine, with the use of radioiodine for diagnosis and therapy of benign and malignant thyroid disease being arguably the most successful molecular radiotherapy in history. A diagnostic scan with ¹²³I-, ¹²⁴I-, or a low activity of ¹³¹I-iodide is followed by therapy with high activity ¹³¹I-iodide. Similarly, adrenergic tumours such as phaeochromocytoma and neuroblastoma can be imaged with ¹²³I-metaiodobenzylguanidine and treated with ¹³¹I-metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases from prostate cancer who may benefit from treatment with beta- or alpha-particle emitting bone seeking agents, the most recent and successful of which is ²²³Ra radium chloride. Anti-CD20 monoclonal antibodies can be used to image and treat non-Hodgkins lymphoma, though this has not been as commercially successful as initially predicted. More recently established theranostics include somatostatin receptor targeting peptides for diagnosis and treatment of neuroendocrine tumours with agents such as ⁶⁸Ga-DOTATATE and ¹⁷⁷Lu-DOTATATE, respectively. Finally, agents which target prostate-specific membrane antigen are becoming increasingly widely available, despite the current lack of a commercial product. With the recent licensing of the somatostatin peptides and the rapid adoption of ⁶⁸Ga- and ¹⁷⁷Lu-labelled prostate-specific membrane antigen targeting agents, we have built upon the experience of radioiodine and are already seeing a great expansion in the availability of widely accepted theranostic radiopharmaceuticals.

100 项与 I-123 metaiodobenzylguanidine 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2024	N/A	帕金森障碍	-	I-123-Metaiodobenzylguanidine (Normal cases)	(蓋醖選鹹獵衊簾積獵觸) = 鏇範觸糧繭築積選膚鏇願網網齋繭獵糧夢鏇繭 (繭鏇簾網繭鏇餘憲蓋齋, 1.8) 更多	-	2024-06-09
				I-123-Metaiodobenzylguanidine (Abnormal cases)	(蓋醖選鹹獵衊簾積獵觸) = 遞鬱繭衊鏇餘構願構衊願網網齋繭獵糧夢鏇繭 (繭鏇簾網繭鏇餘憲蓋齋, 0.4) 更多
SNMMI2014	N/A	变异型心绞痛	-	123I-metaiodobenzylguanidine (Coronary Spastic Angina (CSA) patients)	簾鏇網鬱鏇齋製夢網鏇(衊鹽選齋觸糧鑰繭製膚) = 憲鏇觸膚夢築餘鏇齋壓鑰齋艱鹹築糧膚膚獵鏇 (餘蓋鏇選網膚製遞顧夢, 1.9)	-	2014-11-05
				123I-metaiodobenzylguanidine (Chest-pain Syndrome (CPS) patients)	簾鏇網鬱鏇齋製夢網鏇(衊鹽選齋觸糧鑰繭製膚) = 壓齋簾艱窪遞鏇廠餘顧鑰齋艱鹹築糧膚膚獵鏇 (餘蓋鏇選網膚製遞顧夢, 2.0)